Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026GuruFocus · 1 day ago
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026PRNewsWire · 1 day ago
Jazz Pharmaceuticals PLC $JAZZ Position Lifted by CWA Asset Management Group LLCDefense World · 5 days ago
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026PRNewsWire · 5 days ago
Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?Zacks Investment Research · Oct 16, 2026
Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings StorySeeking Alpha · Oct 15, 2026Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | $6.18 | $5.71 | Miss |
| May 5, 2026 | $4.64 | $6.34 | Beat |
| Feb 24, 2026 | $6.52 | $6.64 | Beat |
| Nov 5, 2025 | $5.95 | $8.13 | Beat |
| Aug 5, 2025 | -$6.12 | -$8.25 | Miss |
| May 6, 2025 | $4.51 | $1.68 | Miss |